Very low prevalence of vaccine human papillomavirus (HPV) types among 18 to 35 year old Australian women, nine years following implementation of vaccination

Introduction: A quadrivalent human papillomavirus vaccination program targeting females aged 12–13 commenced in Australia in 2007, with catch-up vaccination of 14–26 year olds through 2009. We evaluated the program’s impact on HPV prevalence among women aged 18–35 in 2015. Methods: HPV prevalence among women aged 18–24 and 25–35 was compared with prevalence among women in these age groups in 2005–2007. For women aged 18–24, we also compared prevalence with that in a post-vaccine study conducted in 2010–2012. Results: For the 2015 sample, the National HPV Vaccination Register-confirmed three-dose coverage was 53.3% (65.0% and 40.3% among those aged 18–24 and 25–35, respectively). Prevalence of vaccine HPV types decreased from 22.7% (2005–2007) and 7.3% (2010–2012), to 1.5% (2015) (p-trend